Data Sheet 1_Effects of dapagliflozin on myocardial motion parameters and cardiac electrop

262 patients with type 2 diabetes mellitus and coronary heart disease were studied retrospectively between January 2021 and January 2025. The dataset, authored by Fang Liu and shared under a CC-BY-4.0 license, compares conventional therapy to treatment with dapagliflozin over a 4-week period. It includes assessments of cardiac function, myocardial motion, electrophysiological activity, exercise tolerance, and adverse events.

Use Cases

• Compare treatment efficacy based on clinical outcome rates mentioned in the description
• Analyze changes in cardiac function based on echocardiographic and myocardial strain parameters
• Investigate drug safety profiles based on adverse cardiovascular event data
• Model relationships between electrophysiological activity and exercise tolerance improvements

Strengths

• Dataset includes 262 patient records with a defined treatment period of 4 weeks
• Study design compares two distinct treatment groups (n=137 conventional, n=125 dapagliflozin)
• License is permissive (CC-BY-4.0) for reuse and analysis

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect temporal bias inherent to the 2021-2025 study period

Provenance

Source

figshare

Collection Method

Retrospective clinical study

Time Range

January 2021 to January 2025

Freshness

Last updated 2026-06-04 04:27:31; freshness should be verified